After a number of people in the Juicebox Podcast private Facebook group reported having trouble getting some of their Novo Nordisk brand insulins, I reached out to Novo Nordisk to see if I could learn more. Their responses is below.

Novo Nordisk is currently experiencing some supply disruptions causing pockets of stock outages for several of our products across the US, including our insulins. At this time, shortages are being seen across our portfolio of insulin products. The disruption was caused by a temporary manufacturing issue that has now been resolved as well as general COVID-related shipping delays and materials sourcing. Importantly, supply is now consistently shipping out across the US from our warehouses, and we expect stock in pharmacies to be normalized in December.  There are no supply issues impacting the Novo Nordisk GLP-1 diabetes products (Victoza, Ozempic, Rybelsus).

We encourage anyone who needs medicine now and can’t get it to speak to their health care provider about an appropriate treatment plan. We know this is a source of frustration and concern for those who rely on our medicines. We take our responsibility very seriously to supply the market with our medicine and we’re working hard to rectify the situation.